EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience

Cher Wei Chuah iD, Jessica Eldredge, Annabel Magoffin, Edward Vincent O'Loughlin, Calvin Joomann Park, Juliana Puppi, Susan Siew, Michael Stormon, Kunal Thacker, Shoma Dutt

JPGN Reports · 2026-11 · 7 (4) · 536-543

DOI: 10.1002/jpr3.70208 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JPGN Reports, online erschienen am 16.07.2026. Verfasst von Cher Wei Chuah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology The Children's Hospital at Westmead Westmead Australia. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the durability and predictors of loss of response of infliximab (IFX) over 2 years in paediatric Crohn's disease (CD) utilizing a proactive therapeutic drug monitoring (TDM) strategy.

Methods

A retrospective, single‐centre cohort study was conducted at The Children's Hospital at Westmead (CHW), Australia, from January 2019 to December 2021. Proactive TDM was performed at induction, end of induction and 6‐monthly thereafter. The primary outcome was switching to a different biologic as a marker of treatment failure. Secondary outcomes of a physician global assessment (PGA) scale, calprotectin, albumin and C‐reactive protein (CRP) levels were collected at induction, end of induction, 1‐year and 2‐year timepoints.

Results

Seventy‐nine patients were included (62% male, median age 13 years). Durability was 96% at 1 year and 88% at 2 years. Nine patients switched biologics with a median time of 57 weeks. Predictors of therapy failure included the need for escalated induction (odds ratio [OR] 8.5, p = 0.01) colonic phenotype (OR 9.7, p < 0.01), and post‐induction calprotectin level above 305 μg/g (positive predictive value 36%) were identified.

Conclusions

Utilizing a proactive TDM results in excellent durability of IFX at 2 years in paediatric CD. Colonic phenotype is an independent predictor for IFX failure, highlighting the need for directed therapy.

Schlagwörter

Stichwörter der Autor:innen

anti‐TNF‐αdrug levelsinflammatory bowel diseasetreatment strategy

Autor:innen und Institutionen

  • Department of Gastroenterology The Children's Hospital at Westmead Westmead Australia.
  • Sydney Adventist Hospital Clinical School, School of Medicine and Psychology Australian National University Canberra Australia.
  • School of Medicine University of Sydney Sydney Australia.
  • Children's Hospital Westmead Clinical School, Sydney School of Medicine University of Sydney Sydney Australia.

ORCID-Profile: Cher Wei Chuah

Zitieren

APA

Chuah, C. W., Eldredge, J., Magoffin, A., O'Loughlin, E. V., Park, C. J., Puppi, J., Siew, S., Stormon, M., Thacker, K., & Dutt, S. (2026). Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience. JPGN Reports, 7(4), 536-543. https://doi.org/10.1002/jpr3.70208

Vancouver

Chuah CW, Eldredge J, Magoffin A, O'Loughlin EV, Park CJ, Puppi J, et al. Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience. JPGN Reports. 2026;7(4):536-543. doi:10.1002/jpr3.70208

BibTeX
@article{Chuah2026,
  author = {Chuah, Cher Wei and Eldredge, Jessica and Magoffin, Annabel and O'Loughlin, Edward Vincent and Park, Calvin Joomann and Puppi, Juliana and Siew, Susan and Stormon, Michael and Thacker, Kunal and Dutt, Shoma},
  title = {Proactive therapeutic drug monitoring of infliximab leads to treatment durability in paediatric Crohn's disease: A single‐centre Australian experience},
  journal = {JPGN Reports},
  year = {2026},
  volume = {7},
  number = {4},
  pages = {536--543},
  doi = {10.1002/jpr3.70208}
}
Kostenlos starten →